Oncotype DX is the first clinically validated commercial genomic assay for patients with DCIS. Oncotype DX reveals the underlying biology that can help guide DCIS treatment decisions by predicting the risk of any local recurrence of breast cancer (DCIS or invasive) and the risk of local invasive carcinoma and allowing for personalized treatment based on tumor biology as determined by the DCIS recurrence score.
Excerpt from “Demystifying DCIS Breast Cancer: Test seeks to predict prognosis and guide treatment decisions,” by Kari Bohlke, ScD, A Woman’s Health:
The Oncotype DX breast cancer test was originally developed for use in certain groups of women with early-stage, invasive breast cancer, but it’s now possible to also use the test to generate a DCIS recurrence score—an indicator of the likelihood that DCIS will recur after treatment with lumpectomy alone.
Read more here: http://dcis411.com/2012/03/11/what-is-oncotype-dx/